Safety, Tolerability And Efficacy Study Of Topical PF-06763809 In Subjects With Mild To Moderate Chronic Plaque Psoriasis

NCT03469336 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

18

Enrollment

INDUSTRY

Sponsor class

Conditions

Psoriasis

Interventions

DRUG: PF-06763809
OTHER: Vehicle
DRUG: Calcipotriene/calcipotriol
DRUG: Betamethasone

Sponsor

Pfizer